The global tendonitis treatment market size was valued at USD 210.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2030. A growing aging population and sports & occupational work injuries & sudden injuries caused due to trauma or physical work are some of the factors that cause tendonitis, thereby contributing to the industry growth. Adolescents are becoming susceptible to arm-, wrist-, and hand-related injuries owing to the increasing usage of electronic devices, thereby, making them more prone to developing tendonitis. The growing prevalence of bone disorders, osteoarthritis, rheumatoid arthritis, and osteoporosis makes the geriatric population group susceptible to tendonitis.
Annually, over 70,000 U.S. individuals suffering from tendonitis miss their work, as per the Bureau of Labor Statistics. As per the WHO estimates in 2021, approximately 1.71 billion individuals globally are affected by musculoskeletal conditions and are prone to tendonitis. The increasing incidence of sports-related injuries due to the increased sports activities is contributing to the market growth. The adoption of healthy habits is increasing with people across the world taking up at least some physical activity regularly, this is anticipated to increase the incidence of sports injuries thereby contributing to the industry growth. Sports injuries make up 12% of the total injuries that are reported at hospitals in the U.S., most of which are tendon-related injuries.
According to a study published by sports medicine professors from Duke University and the University of Virginia, approximately 40 to 50% of competitive runners have suffered from Achilles tendinopathy. The growing incidence of tendonitis in the general population, which accounts for 5 to 10 cases per 100,000 people is attributed to an increase in the market demand during the forecast period. Various treatment options, such as OTC drugs, surgeries, and physical therapy have increased the number of individuals undergoing treatments, which will encourage the industry's growth. Physical therapy is one of the first lines of treatment for people with chronic tendon conditions as it helps in eccentric strengthening and is effective to treat chronic tendon conditions.
According to the international journal of physiotherapy, physical therapy is efficient to treat lower limb and upper limb tendinopathies, and these factors are attributed to an increase in the demand for the market during the forecast period. Tendons are highly aligned connective tissues that help transmit force from muscles to bones, hence these tissues are at a higher risk to get injured; over 32 million tendon-related injuries are reported every year, and tendinopathies are 50% of the injuries reported in sports players, and athletes. Sudden injuries, prolonged inactivity, and treatment-associated side effects are attributed to drive the industry during the forecast period.
Continuous innovations in tendon replacement and regeneration techniques addressing the growing demand for alternative engineered tissue are driving the industry. The tendonitis treatment business globally has been negatively impacted by the COVID-19 pandemic. After the onset of the pandemic, non-essential surgeries were rescheduled due to the sudden increase in the requirement of hospital beds to treat COVID-19-infected patients, thereby hampering the industry's growth. Shortage of personal protective gear and infrastructural restructuring forced healthcare units to prioritize and reschedule surgical procedures. Treatment options, such as physical therapy and surgical procedures, were not considered essential and were therefore rescheduled, which hampered the growth.
Pandemic Impact |
Post COVID Outlook |
The market decreased by 3.4% from 2019 to 2020 |
The market is estimated to witness a year-on-year growth of approximately 2.0% to 2.6% in the next five years. |
Factors, such as shortage of Personal Protective Equipment (PPE) and trained workforce and restrictions and lockdowns forced the healthcare facilities to reschedule and prioritize procedures as essential or nonessential. During the pandemic, several physical therapies and surgical procedures for tendonitis treatment were not considered essential, which can be attributed to a decline in market growth during the pandemic. |
The healthcare facilities are focused on developing strategies to restart elective surgeries such as septic disorders and traumatic tendon injuries once the pandemic stabilizes. Moreover, management of delayed tendonitis-related trauma and sudden injuries is going to be a key task by the majority of healthcare facilities. |
The pandemic affected manufacturing, supply chains, product distribution, operations, and other business activities, of the key players. Various companies operating in the market have reported a decline in sales of their products meant for tendonitis treatment. |
The healthcare facilities and various elbow and shoulder surgeons worldwide are evaluating their perception of emergency, and are actively focused to predict the “new normal” with changed priority order for treatment procedures in the forthcoming post-COVID scenario, thereby providing affirmative growth prospects in the upcoming years. |
The supply chain constraints affected manufacturing and other business activities. Several key players worldwide reported a dip in sales of their products thereby reducing the market growth. However, returning to normalcy, the healthcare units are strategizing their approaches toward managing and restarting elective surgeries, such as traumatic tendon injuries. The growing popularity of minimally invasive procedures and the increase in government initiatives to raise awareness about sports injuries are driving the key participants to develop solutions, such as tendon reinforcement and artificial tendons. Key players are focused on revising their product development & expansion strategies through mergers & acquisitions and collaborations, providing them with a competitive edge in the industry.
In 2022, the therapy segment dominated the global industry and accounted for the largest share of more than 70.9% of the overall revenue. The increasing preference of patients with tendonitis for non-invasive treatments is attributed to contributing to segment growth. The physical therapy sub-segment accounted for the largest market share in the therapy segment owing to it being the first line of treatment for tendonitis as it helps relieve patients with chronic tendon cases. The effectiveness and outcomes of physical therapies, such as quicker relief to patients, are expected to boost the growth of the sub-segment.
However, other therapies, such as shockwave therapy and hot & cold therapy, are gaining popularity and are anticipated to grow significantly over the forecast years. Apart from physical therapy, NSAIDs are given to patients for the preliminary treatment of tendonitis. Surgical procedures are considered the last solution in the plan of treatment for severely damaged tendons, which cannot be treated through pharmacological therapies. Despite the availability of surgical procedures for tendonitis treatment, physical therapy is preferred by the patients due to the slower healing time as compared to the therapy options, which provide faster relief.
In 2022, the Achilles tendonitis segment dominated the global industry and accounted for the largest share of more than 48.6% of the total revenue. The Achilles tendon is the largest in the human body. The Achilles tendon can endure strain and rupture from running and jumping, which causes tendinitis. Achilles tendonitis affects 5 to 10 per 100,000 people with 80% of the ruptures occurring during recreational sports. The incidence of Achilles tendinitis is 24% in athletes with 18% sustained by athletes before the age of 45 years. These factors are attributed to the increase in the growth of the segment during the forecast period.
The golfer’s elbow segment is anticipated to register the fastest CAGR rate over the forecast period due to the rising prevalence of lateral elbow tendinopathy and medial elbow tendinopathy. According to an article published by the NCBI in May 2018, golfer’s elbow commonly occurs in the population age group of 40 to 60 years, affecting males and females at the same rate. Growing geriatric population and changing lifestyles with people being inclined toward some sort of physical activity that includes sports activities increase the risk of injuries, thereby contributing to the growth of elbow tendinopathy. Innovative product launches and cost-effective treatment solutions to cure golfer’s elbow are also driving the segment.
In 2022, North America dominated the global industry and accounted for the largest share of 43.0% of the overall revenue. A growing number of surgeries performed for tendonitis in the region and increasing consumer disposable income levels are among the few factors that contribute to the region’s growth. The emergence of local manufacturers of medical devices and collaborations amidst established & renowned players is creating significant growth opportunities for the industry in this region. Research activities undertaken by the key players in this region to expand product portfolios and business geographies are also attributed to accelerating the regional market growth over the forecast period.
In addition, increasing cases of sports-related injuries are attributed to contributing to the growth of the market. On the other hand, Asia Pacific is anticipated to register the fastest growth rate during the forecast period. The rapid growth can be attributed to the presence and development of advanced healthcare facilities offering surgical procedures and therapies. Medical experts, physicians, and surgeons from various other countries and regions have aligned with Asia Pacific healthcare facilities to support the development of patient-centric treatment protocols and guidelines, thereby, enhancing the quality of care.
Tendon-related injuries are common in athletes and sports players, the increasing incidence of such injuries in the population is attributed to a rise in the demand for tendonitis treatment solutions over the forecast period. Addressing the growing demand, industry participants are devising product development strategies and undertaking various initiatives to expand their business footprint. The balanced presence of local manufacturers and well-established organizations operating across global markets is one of the key driving forces of the industry. Some of the prominent players in the global tendonitis treatment market include:
Merck and Co., Inc.
Bayer AG
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Abbott
Pfizer
GlaxoSmithKline PLC
Almatica Pharma, Inc.
Teva Pharmaceuticals Industries
Report Attribute |
Details |
Market size value in 2023 |
USD 221.2 billion |
Revenue forecast in 2030 |
USD 281.8 billion |
Growth rate |
CAGR of 3.5% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Treatment, condition, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; Spain; Italy; France; Russia; Japan; China; India; Singapore; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Merck and Co. Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Abbott; Pfizer; GlaxoSmithKline PLC; Almatica Pharma, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research, Inc. has segmented the global tendonitis treatment market report on the basis of treatment, condition, and region:
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Therapy
Hot and Cold Therapy
Physical Therapy
Shockwave Therapy
Surgery
Condition Outlook (Revenue, USD Million, 2018 - 2030)
Tennis Elbow
Golfer’s Elbow
Pitcher’s Elbow
Jumper’s Knee
Swimmer’s Shoulder
Achilles Tendonitis
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
Spain
France
Sweden
Denmark
Norway
Asia Pacific
China
India
Japan
Thailand
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
b. The global tendonitis treatment market size was estimated at USD 210.1 billion in 2022 and is expected to reach USD 221.2 billion in 2023.
b. The global tendonitis treatment market is expected to grow at a compound annual growth rate of 3.5% from 2023 to 2030 to reach USD 281.8 billion by 2030.
b. North America dominated the tendonitis treatment market with a share of 43.0% in 2022. This is attributable to the growing number of tendonitis surgeries performed in the region and rising disposable income.
b. Some key players operating in the tendonitis treatment market include Merck and Co. Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Abbott; Pfizer; GlaxoSmithKline PLC; Almatica Pharma, Inc.
b. Key factors that are driving the tendonitis treatment market growth include increasing incidence of tendonitis due to growth in the aging population, sports & occupational work injuries, and sudden injuries caused due to physical exercise and trauma.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.